Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

4.40USD
7:23pm BST
Change (% chg)

$0.15 (+3.53%)
Prev Close
$4.25
Open
$4.20
Day's High
$4.43
Day's Low
$4.20
Volume
60,917
Avg. Vol
177,290
52-wk High
$7.35
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Affimed NV ::AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS.AFFIMED NV - TO RECEIVE $96 MILLION UPFRONT AND COMMITTED FUNDING AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $5.0 BILLION INCLUDING MILESTONE PAYMENTS.AFFIMED NV - ADDITIONAL $5.0 BILLION CO MAY RECEIVE ALSO INCLUDES ROYALTIES ON SALES.  Full Article

Affimed Appoints Dr. Leila Alland As Chief Medical Officer
Monday, 19 Mar 2018 

March 19 (Reuters) - Affimed Nv ::AFFIMED APPOINTS DR. LEILA ALLAND AS CHIEF MEDICAL OFFICER.AFFIMED NV - ‍APPOINTMENT OF LEILA ALLAND TO POSITION OF CHIEF MEDICAL OFFICER (CMO), EFFECTIVE MARCH 26​.  Full Article

Affimed reports Q3 loss per share EUR 0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Affimed Nv :Affimed reports financial results for third quarter 2017.Q3 loss per share EUR 0.18.Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S.Q3 revenue eur 500,000 versus EUR 900,000.Q3 revenue view EUR 933,000 -- Thomson Reuters I/B/E/S.  Full Article

Affimed announces Q3 financial results and corporate update conference call
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Affimed Nv :Affimed announces third quarter 2017 financial results and corporate update conference call.  Full Article